Effects of menopausal hormone replacement therapy on cardiovascular risk;Effets du traitement hormonal substitutif de la ménopause sur le risque cardiovasculaire: Plaidoyer pour un essai européen

Presse Medicale

Volumn 31, Issue 10, 2002, Pages 468-475

  Kuttenn, F ^a   Gerson, M ^a   De Ligneres B ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

BLOOD FLOW; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; EUROPE; FIRST PASS EFFECT; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSE; REVIEW;

ADMINISTRATION, CUTANEOUS; AGED; CORONARY ARTERIOSCLEROSIS; ESTROGENS; EUROPE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT;

EID: 0037117115     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Relation between coronary risk of coronary mortality in women of the Renfrew and Paisley survey: Comparison with men
2. Hormones and heart disease in women: Heart and estrogen/progestin replacement study in perspective
3. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of french women
4. Coronary heart disease risk factors and menopause: A study in 1684 french women
5. Menopause is associated with reduced protection from postprandial lipemia
6. Small low-density lipoprotein particles in women with natural or surgically induced menopause
7. Changes in LDL density across the menopausal transition
8. Transdermal estrogen replacement therapy: Beneficial effects on hemostatic risk factors for cardiovascular disease
9. Menopause and risk of cardiovascular disease. The Framingham study
10. Age at menopause as a risk factor for cardiovascular mortality
11. Postmenopausal oestrogen use, cigarette smoking, and cardiovascular morbidity in women over 50
12. Prostmenopausal oestrogen and Progestin use and the risk of cardiovascular disease
13. Hormone replacement therapy and heart disease prevention
14. Postmenopausal oestrogen and prevention bias
15. Prior to use of estrogen replacement therpay, are users healthiers than nonusers
16. A prospective study of postmenopausal estrogen therapy and coronary heart disease
17. Cause-specific mortality in women receiving hormone replacement therapy
18. Myocardial infarction and the use of oestrogen and oestrogen-progestogen in postmenopausal women
19. Postmenopausal oestrogen treatment and stroke: A prospective study
20. Decreased risk of stroke among postmenopausal hormone users
21. Hormone replacement therapy and risk of non-fatal stroke
22. Prospective study of exogenous hormones and risk of pulmonary embolism in woman
23. Risk of venous thromboembolism in users of hormone replacement therapy
24. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
25. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study
26. The effects of hormone replacement therapy on hemostatic variables in women with previous venous thromboembolism-results from a randomized, double blind, clinical trial
27. Risque cardiovasculaire et traitement hormonal substitutif de la ménopause
28. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials
29. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
30. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: A randomized, controlled trial
31. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
32. Postmenopausal hormone therapy increases risk for venous thromboembolic disease
33. A clinical trial of estrogen-replacement-therapy after ischemic stroke
34. Design of the WHI clinical trial and observational study
35. Hormones to prevent coronary disease in women: When are observational studies adequate evidence?
36. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women
37. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women
38. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. The PEPI trial
39. Comparison of transdermal and oral estrogenprogestin replacement therapy: Effects on serum lipids and lipoproteins
40. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic associatio with Utrogestan in menopausal women
41. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women
42. Lipid transfer reactions and lipid composition of low-density lipoprotein particles in postmenopausal women receiving estrogen
43. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women
44. Transdermal estrogen replacement therapy and plasma lipids in 693 french women
45. Estrogen synthesis, estrogen metabolism and functional estrogen receptors in rat arterial smooth muscle cells in culture
46. Inhibition of coronary artery atherosclerosis by 17b-estradiol in ovariectomized monkeys
47. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys
48. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy
49. Effect of alteration in triglyceride levesl on factor VII-phospholipid complexes in plasma
50. Triglyceride dependence of factor VII coagulant activity in deep venus thrombosis
51. Coagulation activation following estrogen administration to postmenopausal women
52. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women
53. Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women
54. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation(resistance to activated protein C)
55. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy
56. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women
57. Effect of postmenopausal hormones on inflammation-sensitive proteins
58. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes
59. Medroxyprogesterone acetate antagonizes inhibitory effects or conjugated equine estrogens on coronary artery atherosclerosis
60. Effects of estrogen and progestin on aortic size and compliance in postmenopausal women
61. Estradiol therapy combined with progesterone and endothelium-dependent vasodilatation in postmenopausal women
62. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm
63. The case for a nonplasma lipoprotein etiology of reduced vascular risk in estrogen replacement therapy